Literature DB >> 23070249

A novel EGFR mutation in exon 18 with high sensitivity to EGFR TKI treatment with reduced dose.

Erika P Brandão, Marcos Gustavo Pantarotto, Marcelo Cruz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23070249     DOI： 10.1097/JTO.0b013e31826d8f66

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.

Authors:  Eamon M Berge; Dara L Aisner; Robert C Doebele
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

2.  Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors.

Authors:  Jéssica Ribeiro Gomes; Marcelo Rocha S Cruz
Journal:  Onco Targets Ther       Date:  2015-05-19       Impact factor: 4.147

3.  Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature.

Authors:  Lin Li
Journal:  Heliyon       Date:  2022-08-28

Review 4.  Emerging non-invasive detection methodologies for lung cancer.

Authors:  Zhen Li; Jinian Shu; Bo Yang; Zuojian Zhang; Jingyun Huang; Yang Chen
Journal:  Oncol Lett       Date:  2020-03-12       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.